Skip to main content
. 2022 Jul 16;15:69–85. doi: 10.2147/TACG.S365613

Table 4.

Relation Between High and Low Expression of CircANAX2 Expression with Clinical Data in AML Patients (N = 66)

CircANAX2 Expression Test of Sig. p
Low Median (<12.97) (n=33) High Median (>12.97) (n=33)
No. % No. %
Sex
 Male 18 54.5 19 57.6 χ2=0.062 0.804
 Female 15 45.5 14 42.4
Age (years)
 Min. – Max. 19.0–75.0 22.0–75.0 t=1.039 0.303
 Mean ± SD. 49.09 ± 15.16 53.0 ± 15.42
 Median (IQR) 50.0 56.0
Splenomegaly 8 24.2 18 54.5 χ2=6.346 0.012*
Hepatomegaly 8 24.2 17 51.5 χ2=5.216 0.022*
Lymphadenopathy 2 6.1 2 6.1 χ2=0.0 FEp=1.000
CNS involvement 0 0.0 2 6.1 χ2=2.063 FEp=0.492
B.M BLASTS
 Min. – Max. 20.0–90.0 20.0–90.0 U=461.0 0.278
 Mean ± SD. 40.52 ± 23.24 44.91 ± 23.70
 Median 30.0 33.0
FAB
 M1 3 9.1 5 15.2 χ2=23.474 MCp=0.001*
 M2 8 24.2 5 15.2
 M3 11 33.3 0 0.0
 M4 6 18.2 5 15.2
 M5 3 9.1 8 24.2
 M6 2 6.1 3 9.1
 M7 0 0.0 7 21.2
Overall survival (months)
 Min. – Max. 1.0–12.0 1.0–12.0 U=261.50 <0.001*
 Mean ± SD. 10.03 ± 3.45 5.88 ± 4.13
 Median 12.0 4.0
Outcome
 Died 7 21.2 22 66.7 χ2=15.265 MCp<0.001*
 Alive 23 69.7 8 24.2
 Lost FU 3 9.1 3 9.1
Cytogenetic criteria
 Favorable 24 72.7 9 27.3 χ2=17.0 <0.001*
 Intermediate 7 21.2 9 27.3
 Adverse 2 6.1 15 45.4
CR achievement 23 69.7 8 24.2 χ2=13.687 <0.001*
TLC x 103
 Min. – Max. 0.80–23.0 1.10–21.0 U=538.50 0.939
 Mean ± SD. 8.88 ± 6.60 8.95 ± 6.65
 Median 7.50 7.0
Hb gm/dl
 Min. – Max. 3.0–11.80 4.90–11.30 t=0.411 0.682
 Mean ± SD. 8.45 ± 1.86 8.26 ± 1.86
 Median 8.30 8.80
PLT x 103
 Min. – Max. 17.0–120.0 10.0–150.0 U=521.0 0.763
 Mean ± SD. 55.61 ± 25.84 54.73 ± 32.83
 Median 55.0 56.0

Notes: p, p-value for comparing between different parameters *statistically significant at p ≤ 0.05.

Abbreviations: χ2, chi-square test; MC, Monte Carlo; FE, Fisher Exact; t, Student’s t-test, U; Mann Whitney test.